Cosmos Health Inc. (COSM)

Cosmos Health Inc. has announced the early retirement of an $8 million senior secured convertible note issued to ATW, a full year ahead of its August 2027 maturity date. This move strengthens the company's balance sheet by eliminating potential future conversions and dilution. The company also reported improvements in its financial health, including reduced liabilities and increased stockholders' equity, alongside ongoing digital asset holdings and a share repurchase program.

Cosmos Health Inc. (NASDAQ:COSM) anticipates its new nutraceutical product, Oliv18, will generate over $6 million in additional annual U.S. revenue within the next 12 to 18 months. The company expects this product, a USDA and EU organic certified whole olive polyphenol formulation targeting cardiovascular health, to yield approximately $4.3 million in gross profit with a 72% gross margin. The rollout will begin with e-commerce, expanding to retail channels, and is based on internal projections including pricing and distribution growth.

Cosmos Health (NASDAQ: COSM) projects its Oliv18™ whole-olive polyphenol nutraceutical to generate over $6 million in incremental annual U.S. revenue within 12–18 months, with an estimated $4.3 million gross profit at a 72% gross margin. The product targets the U.S. cardiovascular health and antioxidant supplement markets and will be rolled out in stages, beginning with direct-to-consumer e-commerce before expanding to selected retail channels. This forecast relies on internal assumptions and successful execution of commercialization plans, leveraging the growing cardiovascular and antioxidant supplement markets, estimated at $2.11 billion in 2024 and $1.66 billion in 2025, respectively.

Cosmos Health (NASDAQ: COSM) reported strong Q2 financial results, with revenues up 30% year-over-year in H1 and a strengthened balance sheet. The company also announced a significant five-year exclusive deal with Innova Healthcare to launch its Sky Premium Life brand in Saudi Arabia, projecting over 5 million units in sales. Additionally, Cosmos Health expanded its manufacturing capabilities and grew its Cosmofarm network.

Cosmos Health Inc (COSM) has entered a five-year distribution agreement with Innova Healthcare to sell its Sky Premium Life nutraceutical products in Saudi Arabia, with an initial order of 126,000 units. Despite a GF Value™ suggesting it is 40% undervalued, the company exhibits weak financial fundamentals, including persistent losses and a low GF Score™ of 29/100, indicating significant risks. While insiders have purchased $1.7 million in shares, no premium gurus currently hold COSM stock.